676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84)

676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84)

Bibliographic Details
Main Authors: Elizabeth Evans, Nagashree Seetharamu, Crystal Mallow, Maurice Zauderer, Barbara Burtness, Marya Chaney, Alexander Spira, Conor Steuer, Tarek Mekhail, J Thaddeus Beck, Douglas Adkins, Terrence Fisher, Amber Foster, John Leonard, Nabil F Saba, Megan Baumgart, Steven Hager, Christopher Chay
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items

Similar Items